334 related articles for article (PubMed ID: 2405151)
1. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats.
Le Monnier de Gouville AC; Mondot S; Lippton H; Hyman A; Cavero I
J Pharmacol Exp Ther; 1990 Jan; 252(1):300-11. PubMed ID: 2405151
[TBL] [Abstract][Full Text] [Related]
2. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.
Cavero I; Mondot S; Mestre M
J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353
[TBL] [Abstract][Full Text] [Related]
3. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
Cavero I; Pratz J; Mondot S
Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
[TBL] [Abstract][Full Text] [Related]
4. Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration.
Le Monnier de Gouville AC; Lippton H; Cohen G; Cavero I; Hyman A
J Pharmacol Exp Ther; 1990 Sep; 254(3):1024-8. PubMed ID: 2118569
[TBL] [Abstract][Full Text] [Related]
5. Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats.
Pratz J; Mondot S; Montier F; Cavero I
J Pharmacol Exp Ther; 1991 Jul; 258(1):216-22. PubMed ID: 1906538
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.
Cavero I; Lefevre-Borg F; Lhoste F; Sabatier C; Richer C; Giudicelli JF
J Pharmacol Exp Ther; 1984 Mar; 228(3):779-91. PubMed ID: 6707926
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
Lawson K; Barras M; Zazzi-Sudriez E; Martin DJ; Armstrong JM; Hicks PE
Br J Pharmacol; 1992 Sep; 107(1):58-65. PubMed ID: 1422579
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.
Cavero I; Lorrain J; Di Paola ED; Lhoste F; Payen B; Dennis T; Scatton B
J Pharmacol Exp Ther; 1985 Dec; 235(3):798-809. PubMed ID: 2934543
[TBL] [Abstract][Full Text] [Related]
9. Cross tachyphylaxis to endothelin isopeptide-induced hypotension: a phenomenon not seen with proendothelin.
Le Monnier de Gouville AC; Cavero I
Br J Pharmacol; 1991 Sep; 104(1):77-84. PubMed ID: 1786522
[TBL] [Abstract][Full Text] [Related]
10. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the hemodynamic effects of endothelin-1 and sarafotoxin S6b in conscious rats.
Han SP; Trapani AJ; Fok KF; Westfall TC; Knuepfer MM
J Pharmacol Exp Ther; 1991 Jan; 256(1):183-8. PubMed ID: 1988658
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.
Quast U; Cook NS
J Pharmacol Exp Ther; 1989 Jul; 250(1):261-71. PubMed ID: 2501478
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone.
Cavero I; Lefèvre-Borg F; Gomeni R
J Pharmacol Exp Ther; 1981 Aug; 218(2):515-24. PubMed ID: 7252851
[TBL] [Abstract][Full Text] [Related]
15. SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat.
Le Monnier de Gouville AC; Lawson K; Thiry C; Cavero I
J Pharmacol Exp Ther; 1991 Mar; 256(3):1049-56. PubMed ID: 1672375
[TBL] [Abstract][Full Text] [Related]
16. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of rat calcitonin gene-related peptide in the conscious rat.
Sirén AL; Feuerstein G
J Pharmacol Exp Ther; 1988 Oct; 247(1):69-78. PubMed ID: 2459371
[TBL] [Abstract][Full Text] [Related]
18. Differential pharmacological profile of endothelin-1 and its precursor, big endothelin.
Le Monnier de Gouville AC; Cavero I
J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S362-5. PubMed ID: 1725381
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of endotoxaemia on pressor and vasoconstrictor actions of angiotensin II and arginine vasopressin in conscious rats.
Tarpey SB; Bennett T; Randall MD; Gardiner SM
Br J Pharmacol; 1998 Apr; 123(7):1367-74. PubMed ID: 9579732
[TBL] [Abstract][Full Text] [Related]
20. Studies on the anti-vasoconstrictor activity of BRL 34915 in spontaneously hypertensive rats; a comparison with nifedipine.
Buckingham RE
Br J Pharmacol; 1988 Mar; 93(3):541-52. PubMed ID: 3370388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
